Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Retained Earnings: 2019-2024

Historic Retained Earnings for Benitec Biopharma (BNTC) over the last 6 years, with Jun 2024 value amounting to -$190.3 million.

  • Benitec Biopharma's Retained Earnings fell 18.63% to -$219.4 million in Q1 2025 from the same period last year, while for Mar 2025 it was -$219.4 million, marking a year-over-year decrease of 18.63%. This contributed to the annual value of -$190.3 million for FY2024, which is 13.32% down from last year.
  • As of FY2024, Benitec Biopharma's Retained Earnings stood at -$190.3 million, which was down 13.32% from -$167.9 million recorded in FY2023.
  • In the past 5 years, Benitec Biopharma's Retained Earnings registered a high of -$116.6 million during FY2020, and its lowest value of -$190.3 million during FY2024.
  • Over the past 3 years, Benitec Biopharma's median Retained Earnings value was -$167.9 million (recorded in 2023), while the average stood at -$168.8 million.
  • Data for Benitec Biopharma's Retained Earnings shows a maximum YoY decreased of 13.99% (in 2022) over the last 5 years.
  • Over the past 5 years, Benitec Biopharma's Retained Earnings (Yearly) stood at -$116.6 million in 2020, then decreased by 11.56% to -$130.1 million in 2021, then decreased by 13.99% to -$148.3 million in 2022, then declined by 13.19% to -$167.9 million in 2023, then declined by 13.32% to -$190.3 million in 2024.